The CFO Mr. O'Toole made the statement in the webinar. He may have also said it in the Q call.
Reread the article, it compares advantages and disadvantages of each as stand alone allograft skin substitutes for the standard of care allograft which is cadaver skin. Guess I need to dig up Dr. Carter's webcast.
The CFO Mr. O'Toole made the statement in the webinar. He may...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.65 |
Change
-0.050(1.85%) |
Mkt cap ! $183.5M | |||
| Open | High | Low | Value | Volume |
| $2.64 | $2.68 | $2.63 | $283.6K | 107.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2206 | $2.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.67 | 5477 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVH (ASX) Chart |